Arthritis/new area with arthritis/arthritis in arch feet; Dry mouth; Generalized aching/BODY ACHE; Swelling; Dry eyes; Chills; Headache; This spontaneous case was reported by a patient and describes the occurrence of ARTHRITIS (Arthritis/new area with arthritis/arthritis in arch feet), DRY MOUTH (Dry mouth), PAIN (Generalized aching/BODY ACHE), SWELLING (Swelling) and DRY EYE (Dry eyes) in an adult female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis.    Concurrent medical conditions included Rheumatoid arthritis (MODERATE TO SEVERE).   On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) 40 milligram. On an unknown date, the patient experienced ARTHRITIS (Arthritis/new area with arthritis/arthritis in arch feet), DRY MOUTH (Dry mouth), PAIN (Generalized aching/BODY ACHE), SWELLING (Swelling), DRY EYE (Dry eyes), CHILLS (Chills) and HEADACHE (Headache). At the time of the report, ARTHRITIS (Arthritis/new area with arthritis/arthritis in arch feet), PAIN (Generalized aching/BODY ACHE), SWELLING (Swelling), CHILLS (Chills) and HEADACHE (Headache) had resolved and DRY MOUTH (Dry mouth) and DRY EYE (Dry eyes) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication was reported by reporter. It was unknown if patient was enrolled in a COVID-19 Vaccine Trial. No treatment medication was reported by reporter.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.  Company Comment:  This is a spontaneous case, reported by a patient, concerning an adult female patient of unspecified age with relevant medical condition of moderate to severe Rheumatoid arthritis, who experienced the unexpected non-serious adverse event of special interest Arthritis, reported as new area with arthritis and arthritis in the arch of the feet, in the context of a dose of mRNA-1273 vaccine. Latency cannot be properly assessed since vaccination date nor event onset date were provided. It was reported that the patient also experienced dry mouth and eyes, generalized body ache, swelling, chills, and headache. No further details about the clinical course, diagnostic procedures and treatments were provided. It was reported that the event Arthritis had resolved. The medical condition of moderate to severe Rheumatoid arthritis remains as a confounder for the event Arthritis. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This is a spontaneous case, reported by a patient, concerning an adult female patient of unspecified age with relevant medical condition of moderate to severe Rheumatoid arthritis, who experienced the unexpected non-serious adverse event of special interest Arthritis, reported as new area with arthritis and arthritis in the arch of the feet, in the context of a dose of mRNA-1273 vaccine. Latency cannot be properly assessed since vaccination date nor event onset date were provided. It was reported that the patient also experienced dry mouth and eyes, generalized body ache, swelling, chills, and headache. No further details about the clinical course, diagnostic procedures and treatments were provided. It was reported that the event Arthritis had resolved. The medical condition of moderate to severe Rheumatoid arthritis remains as a confounder for the event Arthritis. The benefit-risk relationship of mRNA-1273 is not affected by this report.